Alivus Life Sciences to Hold Investor Meetings on September 9, 2026
Alivus Life Sciences Limited will conduct one-on-one investor and analyst meetings in Mumbai on September 9, 2026. Participants include Breakout Capital, UTI, Kotak Mutual Fund, and Param Capital. The meetings are in-person.
This is a standard disclosure of investor meetings, which is a routine activity for publicly listed companies and is unlikely to have a significant impact on the stock price or business operations.
The announcement is a routine disclosure of upcoming investor meetings and does not contain any new financial information or significant business developments that would sway sentiment.
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has announced a series of investor and analyst meetings scheduled for September 9, 2026. These meetings will be conducted in-person in Mumbai and will be of a 'One on One' type.
Attendees will include representatives from Breakout Capital, UTI, Kotak Mutual Fund, and Param Capital. The company has noted that the schedule and mode of these meetings may be subject to change due to unforeseen circumstances related to the investor, analyst, or the company itself.
This disclosure is made pursuant to Regulation 30 and Para A of Part A of Schedule III of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The corporate office is located at Technopolis Knowledge Park, Andheri (E), Mumbai, and the registered office is in Solapur.
A plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.
